Global Leukemia Therapeutics Market 2012-2016

Global Leukemia Therapeutics Market 2012-2016

Category : Healthcare

TOLL FREE
+1-971-202-1575
------------ Or -------------
help@researchbeam.com

TechNavio’s analysts forecast the Global Leukemia Therapeutics market to grow at a CAGR of 10 percent over the period 2012-2016. One of the key factors contributing to this market growth is the significant increase in the number of cancer patients worldwide. The Global Leukemia Therapeutics market has also been witnessing an increase in the number of mergers and acquisitions. However, the delay in cancer diagnosis could pose a challenge to the growth of this market. 

TechNavio’s report, Global Leukemia Therapeutics Market 2012-2016, has been prepared based on an in-depth market analysis of the market with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it covers the Global Leukemia Therapeutics market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

The key vendors dominating this market space are Bristol-Myers Squibb Co., Celgene Corp., GlaxoSmithKline plc, Hoffmann-La Roche Ltd., and Novartis AG. 

The other vendors mentioned in the report are Ambit Biosciences Inc., ARIAD Pharmaceuticals Inc., Biogen Idec Inc., Cephalon Inc., Clavis Pharma ASA, Eisai Co. Ltd., ERYTECH Pharma SA, Genmab A/S, Genzyme Corp., Pfizer Inc., Sunesis Pharmaceuticals Inc., Talon Therapeutics Inc., and Teva Pharmaceutical Industries Ltd.

Key questions answered in this report:
What will the market size be in 2016 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of each of these key vendors?

01. Executive Summary

02. Introduction

03. Market Coverage


Market Overview

Key Offerings

04. Market Landscape

04.1 Global Leukemia Therapeutics Market

Market Size

Market Forecast

04.2 Leukemia Therapeutics Market in the US

Market Size and Forecast

04.3 Leukemia Therapeutics Market in Japan

Market Size and Forecast

04.4 Market Segmentation

04.5 Five Forces Analysis

05. Geographical Segmentation

06. Key Leading Countries


US

Japan

UK

07. Rate of Incidence and Prevalence

08. Vendor Landscape

09. Buying Criteria

10. Market Growth Drivers

11. Drivers and Their Impact

12. Market Challenges

13. Impact of Drivers and Challenges

14. Market Trends

15. Key Vendor Analysis


15.1 Bristol-Myers Squibb Co.

Business Overview

Key Information

SWOT Analysis

15.2 Celgene Corp.

Business Overview

Key Information

SWOT Analysis

15.3 GlaxoSmithKline plc

Business Overview

Key Information

SWOT Analysis

15.4 Hoffmann-La Roche Ltd. 

Business Overview

Key Information

SWOT Analysis

15.5 Novartis AG

Business Overview

Key Information

SWOT Analysis

16. Other Reports in this Series



List of Exhibits

Exhibit 1: Global Leukemia Therapeutics Market 2012–2016 (US$ billion)

Exhibit 2: Leukemia Therapeutics Market in the US 2012–2016 (US$ billion)

Exhibit 3: Leukemia Therapeutics Market in Japan 2012–2016 (US$ million)

Exhibit 4: Global Leukemia Therapeutics Market by Category Segmentation

Exhibit 5: Global Leukemia Therapeutics Market by Category Segmentation 2012

Exhibit 6: Global Leukemia Therapeutics Market by Geographical Segmentation   2012

Exhibit 7: Global Leukemia Therapeutics Market by Vendor Segmentation 2012

Exhibit 8: Business Segmentation of Bristol-Myers Squibb Co.

Exhibit 9: Business Segmentation of Celgene Corp. 

Exhibit 10: Business Segmentation of GlaxoSmithKline plc

Exhibit 11: Business Segmentation of Hoffmann-La Roche Ltd.

Exhibit 12: Business Segmentation of Novartis AG



 


Enquiry Before Buy
image
Can´t read the image ? refresh here.